1. Home
  2. MRNS

MRNS

Marinus Pharmaceuticals Inc.

Logo Marinus Pharmaceuticals Inc.

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

as 04-12-2024 4:00pm EST

$
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

Marinus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is focused on developing and commercializing innovative therapeutics to treat epilepsy and neuropsychiatric disorders. Marinus manages the business in one segment, which is the identification and development of neuropsychiatric therapeutics. The Company is developing ganaxolone for multiple epilepsy and other neuropsychiatric indications, including adjunctive, or add-on, therapy for the treatment of drug-resistant focal onset seizures; status epilepticus; Fragile X Syndrome, and PCDH19-RE.

Founded: 2003 Country:
United States
United States
Employees: N/A City: RADNOR
Market Cap: 450.4M IPO Year: 2014
Target Price: $20.50 AVG Volume (30 days): 440.9K
Analyst Decision: Strong Buy Number of Analysts: 8
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -2.63 EPS Growth: N/A
52 Week Low/High: $5.57 - $11.26 Next Earning Date: 05-09-2024
Revenue: $30,989,000 Revenue Growth: 21.63%
Revenue Growth (this year): 33.41% Revenue Growth (next year): 64.37%

Share on Social Networks: